Alacapsin

Quick links to important sections

Alacapsin

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Alacapsin

Quick Facts

Property Description
Active ingredient Capsaicin (INN)
Form Topical Cream, Ointment, or Patch
Pharmacological class Topical Analgesic; TRPV1 Agonist
General purpose Relief of localized aches and pains
Origin Derived from the Capsicum annuum plant

What Type of Medicine is Alacapsin?

Alacapsin is a pharmaceutical preparation classified as a topical analgesic, which places it within the broader group of miscellaneous topical agents for the cutaneous route of administration. This designation means the drug is applied directly to the skin, typically formulated in a dosage form such as a cream or patch, rather than being taken orally. This localized application is clinically recognized for delivering focused relief directly at the area of discomfort. Its therapeutic properties include a classification as a topical analgesic effective for managing pain at the application site.


What is the Active Ingredient in Alacapsin?

The single active ingredient in Alacapsin is Capsaicin, the International Nonproprietary Name (INN) for the molecule 8-methyl-N-vanillyl-trans-6-nonenamide. Capsaicin is a Capsaicinoid compound whose origin lies as a naturally-occurring botanical irritant found in the fruit of the Capsicum annuum plant, the source of chili peppers. However, for use in pharmaceutical preparations, the substance is often a highly purified extract or a synthetic derivation to ensure consistent purity and dosage. As a single-ingredient product, Capsaicin is uniformly integrated into an emollient base to ensure optimal delivery through the skin.


How Does Alacapsin Provide Pain Relief? (High-Level Principle)

Alacapsin's functional principle is based on its role as a Transient Receptor Potential Vanilloid 1 (TRPV1) agonist, a mechanism that modulates sensory neuron signals in the skin. This action creates a distinct effect: after an initial sensory activation, the medication induces neural desensitization, effectively lessening the nerve fibers' ability to transmit pain messages. The primary mechanism involves the temporary depletion of the neurotransmitter Substance P. This focused, local interruption of the pain pathway is the key to Alacapsin's general benefit in relieving discomfort by disrupting the communication of pain signals between nerves.

What side effects are possible with Alacapsin?

Possible side effects and safety information

The official safety profile of Alacapsin, as documented by regulatory authorities, is dominated by reactions occurring at the site of application. These effects are officially classified by their frequency and body system.

Classification Adverse Reactions
Very Common (ge 1/10) Application site pain, Application site erythema (redness)
Common (ge 1/100 to < 1/10) Application site pruritus (itching), Application site edema (swelling), Nausea, Hypertension, Cough
Uncommon (ge 1/1,000 to < 1/100) Dysgeusia (taste perversion), Hypoesthesia, Tachycardia, Urticaria

These reactions are often described as transient and self-limited, meaning they typically resolve on their own. The burning sensation and pain are officially noted to be most intense at the start of treatment or immediately following application.

Serious Adverse Reactions and Constraints

Regulatory documents highlight the rare potential for severe skin burns, including second- and third-degree reports. There is also a documented risk of severe irritation to the eyes, respiratory tract, and mucous membranes if the product is aerosolized or misused, which may lead to coughing or wheezing. Official safety constraints prohibit the use of the product on broken, irritated, or damaged skin or open wounds.

Population-Specific Notes

Safety labeling includes specific considerations for certain patient groups. For individuals with Diabetic Peripheral Neuropathy (DPN), the label notes the necessity of carefully examining the feet for skin lesions before application. Patients with pre-existing sensory deficits should be clinically assessed, as the drug's effect on sensory function must be monitored.

Overdose and Emergency Response

Overdose or severe unintended exposure to topical capsaicin is primarily characterized by severe irritation to the skin, eyes, mucous membranes, and the respiratory tract. Documented manifestations include persistent severe burning and the formation of blistering at the application site. Exposure may also result from accidental inhalation, causing acute coughing or sneezing.

Severe outcomes and potential systemic effects documented in regulatory labeling include transient increases in blood pressure (Hypertension) observed after high-concentration application. Life-threatening events such as seizure, collapse, or severe trouble breathing are noted as triggers for immediate emergency action following accidental overdose or ingestion.

Regulatory documents explicitly state that the management of severe exposure is symptomatic and supportive, as no specific antidote is known. Immediate medical attention must be sought for persistent severe burning or blistering. For the most serious events, including collapse, seizure, or severe respiratory distress, contact emergency services (such as 911 or Poison Control) is required. Blood pressure monitoring is a procedural step mandated after high-concentration exposure.

Therapeutic Uses of Alacapsin

What Alacapsin Treats: Main Uses and Benefits

Targeted Relief for Chronic Neuropathic Pain

This topical medication is commonly used to help with symptoms related to increased neurological or muscular activity, specifically symptoms related to physical discomfort in the form of burning, shooting, or electric-like sensations. It is relevant for easing symptom clusters that require supportive management in conditions characterized by periods of heightened symptoms, such as Postherpetic Neuralgia and Diabetic Peripheral Neuropathy. This relief supports the patient during difficult episodes by easing distress in situations where symptoms interfere with daily functioning.

Support for Enduring Musculoskeletal Aches

Alacapsin is applied in addressing conditions presenting with systemic or localized discomfort, such as the persistent aches and stiffness associated with arthritis and simple backache. The therapeutic approach contributes to improved comfort during symptomatic periods by managing symptoms linked to organ-specific functional stress. Alacapsin is applied in addressing localized pain or sensitivity that creates noticeable functional strain. For many patients seeking focused support:

“It helps ease the overall symptom burden for those experiencing enduring, chronic discomfort.”

This treatment offers symptomatic relief that helps patients cope more steadily with symptom fluctuations in a discrete area of the body.


Quick Fact: Therapeutic Contexts Symptom Domain Conditions Supported Primary Benefit
Neuropathic Aches Postherpetic Neuralgia, Diabetic Neuropathy Eases symptoms of heightened neurological activity
Musculoskeletal Strain Osteoarthritis, Simple Backache Contributes to easing the overall symptom load

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Official Regulatory Eligibility Profile

Alacapsin (a topical capsaicin-based preparation) is subject to strict eligibility rules as defined by governmental regulatory documents. The official labeling dictates who can use the medicine and who is formally prohibited.

Eligibility Status Population/Condition Regulatory Classification
Must NOT Use Known hypersensitivity to the active substance or excipients. Contraindicated
Recommended Use Adults and the Elderly Indicated Population
Use Restricted Application to irritated skin or wounds. Conditional Limitation
Not Recommended Children (under 18 years). Use Not Established

Eligibility to use Alacapsin is conditional on several factors. It is formally contraindicated for patients with a known allergy to the active component. Use is restricted to Adults and the Elderly; the medicine is not recommended for the pediatric population due to insufficient safety data. Furthermore, use is conditional on the physical state of the application area, as it must not be applied to broken or irritated skin. For pregnant or breastfeeding women, the regulatory documentation requires a healthcare specialist to determine the advisability of treatment, placing them in a conditional use category.

What should I know about interactions with other medicines?

The official regulatory profile for Alacapsin is strongly influenced by its topical route of administration and subsequent negligible systemic absorption. This minimal amount of the substance entering the bloodstream means the risk for clinically significant systemic drug-drug interactions is considered low. Official regulatory monographs indicate that the active ingredient is not a known inhibitor or inducer of major cytochrome P450 (CYP) enzymes, effectively minimizing the potential for metabolic interaction with co-administered oral medicines. No formal contraindications based on co-administration with other medicinal products are listed in the official prescribing information. The primary regulatory constraints documented relate to administration procedures and specific conditions.

Interaction Context Regulatory Constraint
Local Pharmacodynamic Co-administration of other topical medicinal products on the same site is restricted.
Product-Substance Exposure of the treated area to external heat sources (e.g., heating pads, hot water, sunlamps) must be avoided immediately before or after use.
Population Note Caution is advised in patients with uncontrolled hypertension or a recent history of cardiovascular/cerebrovascular events, due to the risk of transient blood pressure increases associated with application-related pain.

Mechanism of Action

Primary Action: The TRPV1 Agonist Mechanism

Alacapsin's primary action involves its interaction as an agonist with the Transient Receptor Potential Vanilloid 1 (TRPV1) ion channel on peripheral nociceptive sensory neurons. Binding to the receptor's intracellular domain causes a conformational change that opens the channel, initiating a large influx of positive ions, particularly calcium (Ca^2+). This initial activity depolarizes the nerve membrane, resulting in the discharge of action potentials transmitted as thermal and nociceptive stimuli.

Dual Cascade: Desensitization of Nociceptors

The sustained and excessive calcium influx triggers a unique two-part mechanism leading to subsequent functional antagonism. The high intracellular Ca^2+ concentration causes the receptor to become desensitized and defunctionalized by inactivating the TRPV1 receptor and depleting local stores of neuropeptides, such as Substance P. This process is essential for the sustained functional inactivation of the nociceptive nerve fibers.

Physiological Outcome: Modulating Peripheral Nociceptive Signaling

This mechanistic cascade culminates in the alteration of signaling dynamics within the sensory pathway. By inducing the functional inactivation of the primary nociceptive neurons, Alacapsin contributes to the modulation of exaggerated signaling dynamics within the sensory pathway and localized neurogenic signaling.

Dosage and Administration Information

Alacapsin, whose active ingredient is capsaicin, is administered exclusively via the topical route directly onto the skin. The official use protocol varies significantly depending on the concentration and requires strict adherence to specific administration frequencies and durations. Use is constrained by the rule that the product must be applied only to intact, dry skin, and neither external heat nor tight bandaging should be used on the treated area.

Low-Concentration Use (Creams and Gels)

Low-concentration formulations (e.g., 0.025% to 0.1%) are typically applied by the patient. The standard administration frequency for these forms is three to four times daily. For low-concentration treatment to be fully evaluated, continuous application for three to four consecutive weeks is generally required. If a low-concentration patch is used, it must be removed after a maximum of eight hours. After applying creams or gels, hands must be washed thoroughly with soap and water immediately, unless the hands are the area being treated.

High-Concentration Patch Protocol

The 8% high-concentration patch follows a specialized, intermittent regimen and must be administered by a physician or supervised healthcare professional. The treatment involves a single application of up to four patches and is permitted to be repeated no more frequently than every three months. The application duration is precisely defined by the treatment protocol: it is 60 minutes for certain types of neuropathic discomfort, and 30 minutes when administered on the feet for other conditions. Pretreatment of the site with a topical anesthetic is a required step in this supervised protocol. No dosage adjustments are specified for older adults or those with renal or hepatic impairment.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Alacapsin

Evidence for Use in Chronic Neuropathic Pain

Research has explored Alacapsin's application in the study of pain that arises from nerve damage, focusing on conditions like Postherpetic Neuralgia (PHN) and Diabetic Peripheral Neuropathy (DPN). The core of this evidence comes from Randomized Controlled Trials (RCTs), often then combined into systematic reviews and meta-analyses to look at the overall pattern of the data.

Studies in these adult populations were designed to measure changes in pain intensity using standardized scales, and they also monitored the proportion of participants who reached a predefined level of reported discomfort reduction. The research reports how symptoms evolved and highlights changes measured during the study period in the observed populations. In the case of PHN, the overall evidence has been formally assessed by scientific reviewers as Moderate. For DPN, however, the evidence is limited and sometimes inconsistent, and is formally assessed by reviewers with a Low evidence grading.


Evidence for Use in Enduring Musculoskeletal Aches

Research was conducted to explore Alacapsin's application in chronic pain related to joints and muscles, including Osteoarthritis (OA), particularly in the hand and knee, and other localized back or joint discomfort. As with neuropathic pain, the research primarily relies on Randomized Controlled Trials (RCTs) and subsequent systematic reviews that aggregate the findings.

The studies monitored patient-reported outcomes describing perceived discomfort. Findings describe patterns where changes in pain severity measurements were observed in some participants compared to those receiving a placebo. This collective body of research has been broadly assigned a Moderate evidence level by scientific reviewers.


Evidence Gaps and Areas of Scientific Uncertainty

Scientific reviews consistently point to several limitations that affect the overall understanding of Alacapsin. The certainty remains low in some areas of use due to various factors. Long-term effects are not fully established, as most clinical trials followed participants for a period of only 6 to 12 weeks. Furthermore, comparative evidence is lacking against many alternative treatments. Overall, while studies contribute to the broader evidence landscape, subgroup findings are uncertain, and more research is needed to provide clearer insights into long-term outcomes.

Frequently Asked Questions (FAQ)

Common questions about Alacapsin (FAQ)

Q: How quickly does Alacapsin start working after taking it?

A: According to official product information, the time it takes to notice improvement can vary based on the specific formulation. For low-concentration creams and gels, consistent use for up to two weeks may be required before symptoms begin to improve. For the high-concentration patch, the therapeutic effect can last for months, with the timeframe for full therapeutic benefit often described as up to one week after the single application.


Q: How long does Alacapsin stay in your system?

A: Alacapsin is a topical medicine, and regulatory documents confirm it has minimal systemic absorption, meaning only a very small amount enters the bloodstream. This minimal amount is quickly processed and primarily eliminated through the kidneys. Due to minimal absorption, it is rapidly eliminated from the body and is not expected to remain systemically for an extended period.


Q: Can Alacapsin be taken with blood pressure medication?

A: Since Alacapsin has minimal systemic absorption, the risk of clinically significant drug-drug interactions with oral medications, including blood pressure medicines, is generally considered low. Regulatory documents indicate that caution is necessary for patients with uncontrolled high blood pressure or recent cardiovascular issues, given the potential for temporary blood pressure changes during the application process.


Q: What are the storage requirements for Alacapsin?

A: Official labeling states that Alacapsin should be stored at controlled room temperature, typically between 15^circC and 30^circC (59^circF and 86^circF). It must be safely kept out of the sight and reach of children and pets. Additionally, unused or expired products, especially the patches, must be properly disposed of according to local regulatory guidelines, and should not be placed in household waste.


Q: How long can someone stay on Alacapsin treatment?

A: The treatment duration depends on the formulation used. Low-concentration products are often used for a period of two to four continuous weeks to fully assess their efficacy. The high-concentration patch is an intermittent, single treatment that is permitted to be repeated no more often than every three months.


Q: Is it okay to stop taking Alacapsin suddenly?

A: Regulatory information indicates that because Alacapsin is topical and has minimal absorption into the main body system, abruptly discontinuing its use is generally acceptable. Withdrawal symptoms are not expected.


Q: Can Alacapsin be crushed or chewed?

A: No. Alacapsin is strictly for topical use on the skin and should never be taken by mouth. Regulatory warnings state that altering the product, such as cutting the patch or chewing the product, can cause severe irritation or damage to the eyes, mouth, throat, and respiratory passages.


Q: Is it okay if I occasionally forget to take Alacapsin at the exact time?

A: Official guidance for a missed dose is generally to apply it as soon as it is remembered, provided it is not almost time for the next scheduled dose. To avoid applying too much medicine, regulatory guidelines advise against using a double dose to compensate for a missed one.


Q: Can Alacapsin be taken with herbal remedies like St. John's Wort?

A: Systemic interactions between Alacapsin and oral medicines or herbal products are considered unlikely because the drug has minimal absorption into the body. While the risk of systemic interaction is low, regulatory best practice includes informing a healthcare provider about all concomitant medications, supplements, and herbal products.


Q: Is it normal to feel a tingling sensation when starting Alacapsin?

A: Product labeling indicates that a temporary burning, stinging, or tingling sensation at the application site is a very common and expected reaction. This is due to the drug’s mechanism of action on the sensory nerves and typically lessens after several days of regular use. If the sensation is severe or if blistering occurs, professional medical consultation is indicated.


Q: Is Alacapsin safe for people with kidney problems?

A: Official regulatory documents do not specify a need for dosage adjustments for patients with renal (kidney) impairment. This is consistent with the drug's mechanism of action as a topical agent with very low absorption, suggesting a minimal systemic impact on kidney function.


Q: Is there a generic version of Alacapsin available?

A: The active ingredient in Alacapsin, Capsaicin, is available in various over-the-counter (OTC) and generic prescription topical formulations. It is important that any product used, whether brand-name or generic, matches the specific strength and formulation prescribed.


Q: What is the difference between immediate-release and extended-release Alacapsin?

A: Alacapsin is formulated as two different types of products. The low-concentration creams and gels require multiple daily applications over a period of weeks. The high-concentration patch is applied only once for a short period (30–60 minutes) but is designed to provide sustained relief for up to three months following the single treatment.


Q: Has Alacapsin been approved in countries outside of the US?

A: Yes. The active ingredient, Capsaicin, is recognized by global regulatory bodies, including the European Medicines Agency (EMA), and is approved for pain management use in multiple countries across Europe, North America, and other regions.


Q: Do children or teenagers ever take Alacapsin?

A: Official labeling explicitly states that Alacapsin is not recommended for use in children under 18 years of age. This is because the safety and effectiveness of the product have not been established in the pediatric population. The product is intended for use by adults and the elderly.


Q: Can Alacapsin affect sleep patterns?

A: Alacapsin is not generally associated with effects on sleep. The official lists of common and very common side effects focus mainly on application site reactions. However, in rare instances, nervous system effects, such as nervousness, have been reported which could potentially interfere with sleep.


Q: Is there a risk of weight gain while taking Alacapsin?

A: Weight gain is not listed as a known or common adverse reaction in the official regulatory prescribing information for Alacapsin.


Q: How do doctors monitor the effectiveness of Alacapsin treatment?

A: The effectiveness of Alacapsin is primarily monitored through patient-reported outcomes. Doctors assess the treatment by checking the change in the patient's discomfort level, often using standardized pain intensity scales, and observing the overall evolution of the patient's symptoms during the treatment period.


Q: What is the typical time frame for Alacapsin to show its full effect?

A: For low-concentration products, official directions note that the full effect is typically achieved after two to four consecutive weeks of regular use. For the high-concentration patch, the full therapeutic benefit is generally evaluated one week after the single, supervised application.


Q: Are there specific symptoms that signal Alacapsin is working?

A: The most important signal that Alacapsin is working is a reduction in the patient's reported pain severity. Its mechanism of action is designed to induce a state of neural desensitization, effectively reducing the ability of the nerves to transmit pain signals, leading to the desired relief.


Q: How does Alacapsin affect the body's natural processes?

A: Alacapsin's effect is localized to the site of application. It temporarily modulates the body's natural pain transmission process by interacting with a specific nerve receptor (TRPV1). This causes an initial sensory activation followed by a state of functional desensitization, which disrupts the communication of pain signals.


Q: What is the difference between Alacapsin and a placebo in studies?

A: In clinical trials, a placebo is a product that appears identical to Alacapsin but does not contain the active ingredient (Capsaicin). Studies compare the results of the group receiving the active Alacapsin treatment against the group receiving the placebo to establish the drug's true efficacy and safety profile.

How should Alacapsin be stored and disposed of?

Storage and Disposal Requirements

Alacapsin, which contains Capsaicin, must be stored and handled according to official regulatory conditions to maintain its stability and ensure safety.


Required Storage Conditions

The product must be stored at controlled room temperature, generally defined as 15°C to 30°C (59°F to 86°F). Storage must avoid excessive heat and the product must be protected from excessive moisture.

Child Safety and Disposal

For safety, the medicine must be kept out of the sight and reach of children. The disposal of unused or expired product must follow local requirements and the product must not be disposed of via wastewater or household waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Alacapsin found in:

A-Z Index: